Dr. Stephen Sundlof, Former Director of FDA’s CVM, Joins Kindred Bio
Kindred Bio Appoints Dr. Stephen Sundlof, former Director of Center for Veterinary Medicine at the U.S. Food and Drug Administration, as Senior Vice President of Regulatory Affairs
SAN FRANCISCO - Aug. 22, 2013 - PRLog -- Kindred Biosciences, Inc. (Kindred Bio) announced today that it has appointed Stephen Sundlof, DVM, PhD, former Director of Center for Veterinary Medicine at the U.S. Food and Drug Administration, as its Senior Vice President of Regulatory Affairs.
Dr. Sundlof served as the Director of the veterinary division at the FDA from 1994 to 2008 where he oversaw all veterinary products regulated by the FDA. He also served as the Director of Center for Food Safety and Applied Nutrition at the FDA from 2008 to 2010. Dr. Sundlof began his career in 1980 on the faculty of the University of Florida’s College of Veterinary Medicine. In 1994, FDA Commissioner David Kessler named him the CVM director.
Richard Chin, CEO of Kindred Bio, stated, “We’re very pleased to welcome Steve to the Kindred Bio team. His experience and knowledge will be tremendously valuable as we move forward with our mission of helping companion animals in need.”
Dr. Sundlof stated, “I am looking forward to working with the Kindred Bio and to advancing its promising pipeline. I believe Kindred Bio has an exciting new approach to developing drugs for companion animals.”
About Kindred Bio
“Best Medicines for Our Best Friends”
Kindred Bio is a leading veterinary biotechnology company, focused on developing breakthrough therapies for dogs, cats, and horses. Founded by industry veterans formerly from Genentech and Elan Pharmaceuticals who have experience developing antibody drugs such as Lucentis®, Tysabri®, Xolair®, and Rituxan®, Kindred Bio is committed to bringing the very best science and medicine to companion animals.
Forward-looking statements in this news release involve inherent risks and uncertainties and a number of important factors could cause actual results to differ materially from those contained in such forward-looking statements. These factors include, but are not limited to uncertainties associated with: drug development and regulatory review process, scientific discovery process, competition, pricing environment, financing, intellectual property, and evolution of the companion animal market. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date.
Lucentis® is a registered trademarks of Genentech, Inc. Rituxan® is a registered trademark of Biogen Idec Inc. Xolair® is a registered trademark of Novartis AG Corporation. Tysabri® is a trademark of Elan Pharmaceuticals.
Page Updated Last on: Aug 22, 2013